

# Research Grade Felvizumab

## Summary

---

<b>Catalog No.</b>	DVV02804
<b>Alternative Names</b>	SB 209763, HuRSV19VHFNS/VK, RSHZ19 monoclonal antibody, SB 209763, CAS: 167747-20-8
<b>Clone ID</b>	Felvizumab
<b>Host species</b>	Humanized
<b>Species reactivity</b>	HRSV-A
<b>Form</b>	Liquid
<b>Storage buffer</b>	0.01M PBS, pH 7.4.
<b>Concentration</b>	1 mg/ml
<b>Purity</b>	>95% as determined by SDS-PAGE.
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG1, kappa
<b>Applications</b>	Research Grade Biosimilar
<b>Target</b>	F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
<b>Purification</b>	Protein A/G purified from cell culture supernatant.
<b>Endotoxin level</b>	Please contact with the lab for this information.
<b>Expression system</b>	Mammalian Cells
<b>Accession</b>	P03420

**Stability and Storage**

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.


**Note**

For research use only. Not suitable for clinical or therapeutic use.

## Description


Felvizumab [HuRSV19VHFNS/VK, RSHZ19, RSV monoclonal antibody, SB 209763] is a humanised monoclonal antibody (IgG1) prepared by the humanization of an F protein-specific murine MAb. In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999). RSHZ19 (Felvizumab) RSV This antibody was

## Data Image




SDS-PAGE


SDS PAGE for Felvizumab




Detects HRSV-A2 Pre-F/Fusion glycoprotein F0 Protein in indirect ELISA.



Detects HRSV Post-F/Fusion glycoprotein F0 Protein in indirect ELISA.



Detects HRSV F/Fusion glycoprotein F0 Protein in indirect ELISA.



The purity of this product is >95% as determined by SEC-HPLC.

SEC-HPLC